Cabio Biotech (Wuhan) Co (SHSE:688089) Short-Term Debt & Capital Lease Obligation : ¥23.1 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Cabio Biotech (Wuhan) Co Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Cabio Biotech (Wuhan) Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥23.1 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Cabio Biotech (Wuhan) Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥29.7 Mil.

Cabio Biotech (Wuhan) Co Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Cabio Biotech (Wuhan) Co's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cabio Biotech (Wuhan) Co Short-Term Debt & Capital Lease Obligation Chart

Cabio Biotech (Wuhan) Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.84

31.38

12.10

6.65

Cabio Biotech (Wuhan) Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															11.65	11.93	6.75	6.65	23.09

Cabio Biotech (Wuhan) Co Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Cabio Biotech (Wuhan) Co Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cabio Biotech (Wuhan) Co's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Cabio Biotech (Wuhan) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabio Biotech (Wuhan) Co Ltd (SHSE:688089) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 999, Gaoxin Avenue, East Lake New Technology Development Zone, Hubei Province, Wuhan, CHN, 430075

Website

http://www.cabio.cn

Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.

Executives

Shang Yun	Core technical personnel
Xiao Min	senior management
Wang Hua Biao	Directors, senior managers
Geng An Feng	senior management
Du Bin	Director
Yi Hua Rong	senior management
Ma Tao	senior management
Li Xiang Yu	senior management
Wu Yu Jun	Supervisors
Wang Zhi Ming	senior management
Lu Shu Huan	Core technical personnel
Yi De Wei	Director

Cabio Biotech (Wuhan) Co Headlines

No Headlines